Iovance Biotherapeutics Q1 EPS misses analyst expectations, net loss widens

Iovance Biotherapeutics

07/05/2026 12:24

Overview

U.S. TIL therapy maker's Q1 revenue rose 45% yr/yr on Amtagvi demand

Adjusted EPS for Q1 missed analyst expectations

Company posted wider net loss, citing one-time facility maintenance and expansion costs

Outlook

Company sees 2Q26 revenue of $86 mln to $88 mln

Iovance expects FY26 revenue of $350 mln to $370 mln

Company expects increasing Amtagvi demand and expansion to at least 110 ATCs by year-end 2026

Result Drivers

AMTAGVI DEMAND - Co said increased demand for Amtagvi, driven by adoption and referrals toward earlier treatment, boosted revenue

FACILITY MAINTENANCE IMPACT - Revenue was affected by maintenance of the Iovance Cell Therapy Center, though the facility has now been expanded to ensure continuous supply

COST REDUCTIONS - R&D expenses decreased by 12% from the prior quarter, attributed to operational efficiencies and ongoing cost discipline

Company press release: ID:nGNX9jSFGW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$71.43 mln
Q1 EPS
Miss
-$0.19
-$0.15 (9 Analysts)
Q1 Net Income
Miss
-$79.05 mln
-$67.36 mln (6 Analysts)
Q1 Operating Income
Miss
-$81.04 mln
-$66.67 mln (6 Analysts)
Q1 Pretax Profit
Miss
-$79.71 mln
-$69.13 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $9.50, about 132.3% above its May 6 closing price of $4.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)